Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
Released On
March 11, 2024
Expires On
March 11, 2025
Media Type
Internet
Completion Time
30 minutes
Specialty
Hematology-Oncology
Topics
Multiple Myeloma
Jointly provided by
This activity is supported by an independent educational grant from Bristol Myers Squibb.
Credit Available
- Physicians - 0.5 AMA PRA Category 1 Credit™
All other participants completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, advanced practice providers, and other health care proffesionals (HCPs) who treat multiple myeloma (MM) patients.
Program Overview
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)–targeted immunotherapies. These agents hold promise for patients who have relapsed from or become refractory to previous therapies—but these additional options make navigating treatment significantly more challenging for clinicians. Furthermore, many current and emerging BCMA-targeted therapies are associated with unique adverse events that may be unfamiliar to clinicians.
In this virtual Q&A activity, experts provide evidence-based responses to challenging questions on incorporating new and emerging BCMA-targeted therapies that achieve durable remission for RRMM patients and minimizing the toxicities associated with their use. The activity includes animated videos demonstrating the mechanisms of action (MOAs) of several BCMA-targeted agents.
Learning Objectives
Upon completion of this activity, participants should be better able to:
* Distinguish between the efficacies, safety profiles, and MOAs of current and emerging BCMA-targeted agents for MM patients who have relapsed from or are resistant to multiple prior therapies
* Summarize the toxicity profiles of BCMA-targeted agents used to treat RRMM, particularly with respect to the immunotherapies most associated with cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS)
* Optimize selection and sequencing of the most appropriate BCMA-targeted therapies for patients with RRMM
Faculty
Eden Biltibo, MD, MS
Faculty Bio
Assistant Professor
Vanderbilt University Medical Center
Nashville, Tennessee
Noopur S. Raje, MD
Faculty Bio
Professor
Massachusetts General Hospital
Boston, Massachusetts
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation. Purdue University College of Pharmacy is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Credit Designation
Purdue University College of Pharmacy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
In accordance with the ACCME Standards for Integrity and Independence, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 24 months with an ineligible company whose products or services are discussed in the CME activity content over which the individual has control.
All of the relevant financial relationships listed for these individuals have been mitigated.
- Eden Biltibo, MD, MS
- Consultant: BeiGene
- Noopur S. Raje, MD
- Consultant: AbbVie, Bristol Myers Squibb, Pfizer, Sanofi, Takeda
- Research: Bluebird Bio
- Scientific Advisory: Caribou Bio, Immuneel
- Consultant: AbbVie, Bristol Myers Squibb, Pfizer, Sanofi, Takeda
- Purdue University College of Pharmacy
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
- MMRF
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.
- RedMedEd
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit, participants must:
- Read the CME the information and faculty disclosures.
- Participate in the online activity by reading through each question and answer.
- Complete the posttest and evaluation.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Windows XP and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, Purdue University College of Pharmacy, the MMRF, and Bristol Myers Squibb do not recommend the use of any agent outside the labeled indications.
Disclaimer
The information presented in this activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, Purdue University College of Pharmacy, the MMRF, or Bristol Myers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information
For CME questions please contact: [email protected].
Technical Support: If you have any technical problems or playback issues, email us at [email protected].
Copyright © 2024 This CME-certified program is held as copyrighted by Purdue University College of Pharmacy, RedMedEd, and the MMRF. Through this notice, Purdue University College of Pharmacy, RedMedEd, and the MMRF grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.